Market Overview

A Peek Into The Market Before The Trading Starts

Related FFIV
Benzinga's Top Downgrades
Baird Downgrades F5 Networks To Neutral
Tech Sector Lags as EMC, Juniper Sink (Fox Business)
Related ACHC
Lifepoint Hospitals (LPNT) Worth Watching: Stock Gains 7.3% - Tale of the Tape
Tenet Healthcare Extends Contract with Humana to Drive Growth

Pre-open movers US stock futures are lower this morning, as investors are awaiting jobs report. Futures for the Dow Jones Industrial Average dropped 58 points to 14,460.00 and S&P 500 index futures fell 8.10 points to 1,546.40. Nasdaq 100 futures declined 17 points to 2,768.00.

A Peek Into Global Markets European markets were lower today. The STOXX Europe 600 Index fell 0.58%, London's FTSE 100 Index dropped 0.65%, French CAC 40 Index declined 0.77% and German DAX 30 index fell 0.21%.

Asian markets ended mostly lower, with Japan's Nikkei Stock Average rising 1.58% and Australia's S&P/ASX 200 dropping 0.41%. Hong Kong's Hang Seng fell 2.73% and India's Sensex dipped 0.47%.

Broker Recommendation Analysts at Piper Jaffray downgraded F5 Networks (NASDAQ: FFIV) from “overweight” to “neutral.” The target price for F5 Networks has been lowered from $107 to $82.

F5 Networks shares closed at $90.42 yesterday.

Breaking news

  • Acadia Healthcare (NASDAQ: ACHC) today announced that it has signed a definitive purchase agreement with Ten Broeck Tampa, Inc. and Capestrano Investment Company, Inc. to purchase two acute inpatient psychiatric facilities. To read the full news, click here.
  • AstraZeneca (NYSE: AZN) today announced top-line results of OSKIRA-1, a Phase 3 study to assess the efficacy and safety of fostamatinib, the first oral spleen tyrosine kinase (SYK) inhibitor in development for rheumatoid arthritis (RA). OSKIRA-1 had two primary endpoints: assessing signs and symptoms of RA as measured by ACR20 response rates, and an X-ray endpoint known as mTSS (modified Total Sharp Score). To read the full news, click here.
  • Emergent BioSolutions (NYSE: EBS) today announced its decision to expand the protocol for its ongoing Phase 1b, single arm, open label study (Protocol 16009) evaluating the safety and efficacy of TRU-016 in combination with rituximab in previously untreated patients with chronic lymphocytic leukemia (CLL). To read the full news, click here.
  • EntreMed (NASDAQ: ENMD) announced today that its Board of Directors has appointed two new individuals as directors. Joining the Board are James Huang and Y. Alexander Wu, Ph.D. To read the full news, click here.

Posted-In: Piper Jaffray US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Related Articles (AZN + ACHC)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional